Search Within

GME, Medicine

Formats
  1. Meeting Abstract (757)
  2. Journal Article (571)
  3. Review (146)
  4. Editorial (65)
  5. Research Letter (61)
  6. Correspondence (24)
  7. Guidelines (6)
  8. Miscellaneous (6)
  9. Book Section (5)
  10. Conference Paper (4)
Groups
  1. Graduate Medical Education (1645)
  2. Department of Medicine (1296)
  3. Hematology-Oncology Fellows (1096)
  4. Hematologic Malignancies, Division of (779)
  5. Solid Tumor Oncology Division (649)
  6. Weinberg Fellows (623)

More Groups

People
  1. Gunjan Shah (156)
  2. Kylee Maclachlan (155)
  3. Michael Scordo (148)
  4. Saad Usmani (136)
  5. Sergio Giralt (134)
  6. Alexander Lesokhin (120)

More People

Years
  1. 2025 (173)
  2. 2024 (426)
  3. 2023 (404)
  4. 2022 (323)
  5. 2021 (154)
  6. 2020 (73)

More Years

Publications
  1. Blood (311)
  2. Journal of Clinical Oncology (234)
  3. Clinical Lymphoma, Myeloma and Leukemia (46)
  4. Clinical Cancer Research (43)
  5. Annals of Oncology (37)
  6. Blood Advances (34)

More Publications

Publishers
  1. American Society of Hematology (350)
  2. American Society of Clinical Oncology (272)
  3. Elsevier Inc. (206)
  4. Nature Publishing Group (112)
  5. American Association for Cancer Research (101)
  6. Oxford University Press (70)

More Publishers

Results (1645)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Meeting Abstract

    Deschênes-Simard, X.; Bromberg, M.; Devlin, S. M.; Katz, O. B.; Ip, A.; Marcus, R.; Avigdor, A.; Ballweg, A.; Rabinovich, E.; Alhomoud, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Replication stress induces hyper-APOBEC mutagenesis in multiple myeloma
    Meeting Abstract

    Tauro, M.; Panahi, A.; Ziccheddu, B.; Poos, A. M.; Alaoui, A. Y.; Magaletti, D.; Meads, M. B.; Maclachlan, K. H.; Raab, M. S.; Morgan, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and variability based on baseline cytogenetic risk of patients with MDS treated with hypomethylating agents: An analysis from the International Consortium for MDS (icMDS) validate database
    Meeting Abstract

    Getz, T. M.; Kewan, T.; Bewersdorf, J. P.; Stempel, J. M.; Lanino, L.; Wei, W.; Ali, N. H. A.; Dezern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Bleeding in lung cancer patients receiving therapeutic anticoagulation while being treated with VEGF and EGFR inhibitors
    Meeting Abstract

    Fusillo, T. F.; Leader, A.; Mantha, S.; Ajufo, H.; Derkach, A.; Schoenfeld, A.; Singh, R.; Kaplinsky, P.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of efficacy and safety outcomes for lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for the treatment of third-line or later (3L+) relapsed or refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Boardman, A. P.; Reguera, J. L.; Spin, P.; Wang, P.; Almuallem, L.; Ellis, J.; Zheng, J.; Kumar, J.; Farazi, T.; García-Sancho, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Very low dose radiotherapy (VLDRT) with 4 Gy for potentially-curable indolent non-Hodgkin lymphomas
    Meeting Abstract

    Mankuzhy, N. P.; Imber, B. S.; Pammer, P.; Fregonese, B.; Cajo, A.; Cederquist, G.; Dreyfuss, A.; Lapen, K.; Patel, R. R.; Moore, Z. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save